Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1123)	5/20/2003 12:07:13 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1834

Miljenko: So far as I know, rebound insomnia--which by definition is worse than the symptoms that existed before treatment--shows up very quickly. Its duration is often referred to as 'a few days', though I saw something by Henry Roth that cited a "1-2 day" duration. Since he has been NBIX's consultant and guest star on indiplon conference calls, his definition is likely operative at NBIX. I have yet to see a compelling explanation for why it occurs--a sudden exaggerated return of receptor conformation from its altered-by-binding state? That's just an off-the-cuff guess. But my understanding is that, if you don't see it quickly after drug cessation, you won't see it at all. Based on this, two days may indeed be sufficient for a declaration of victory. If there is literature to the contrary, II'd be interested in seeing it. Harry Tracy NeuroInvestment